Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1:14:1172089.
doi: 10.3389/fendo.2023.1172089. eCollection 2023.

COVID-19 vaccine coverage, safety, and perceptions among patients with diabetes mellitus in China: a cross-sectional study

Haolong Li  1 , Fan Ping  2 , Xiaomeng Li  1   3 , Zhihong Wang  4 , Jianzhong Xiao  5 , Hongwei Jiang  6 , Yaoming Xue  7 , Jinxing Quan  8 , Hebin Yao  9 , Xianling Zheng  10 , Yanming Chen  11 , Yufeng Li  12 , Xiaohua Yu  13 , Lingling Xu  14 , Xinxin Feng  1 , Siyu Wang  1 , Yongzhe Li  1 , Xinhua Xiao  2
Affiliations

COVID-19 vaccine coverage, safety, and perceptions among patients with diabetes mellitus in China: a cross-sectional study

Haolong Li et al. Front Endocrinol (Lausanne). .

Abstract

Aims: Diabetes mellitus (DM), one of the most common chronic diseases in China, is a risk factor for SARS-COV-2 infection and poor prognosis of COVID-19. The COVID-19 vaccine is one of the key measures to control the pandemic. However, the actual coverage of COVID-19 vaccination and associated factors remain unclear among DM patients in China. We conducted this study to investigate the COVID-19 vaccine coverage, safety, and perceptions among patients with DM in China.

Methods: A cross-sectional study of a sample of 2200 DM patients from 180 tertiary hospitals in China was performed using a questionnaire developed through the Wen Juan Xing survey platform to collect information regarding their coverage, safety, and perceptions of COVID-19 vaccination. A multinomial logistic regression analysis model was performed to determine any independent relationships with COVID-19 vaccination behavior among DM patients.

Results: In total, 1929 (87.7%) DM patients have received at least one dose COVID-19 vaccine, and 271 (12.3%) DM patients were unvaccinated. In addition, 65.2% (n = 1434) were booster vaccinated against COVID-19, while 16.2% (n = 357) were only fully vaccinated and 6.3% (n = 138) were only partially vaccinated. The prevalence of adverse effects after the first dose of vaccine, the second dose of vaccine, and the third dose of vaccine were 6.0%, 6.0%, and 4.3% respectively. Multinomial logistic regression analysis showed that DM patients complicated with immune and inflammatory diseases (partially vaccinated: OR = 0.12; fully vaccinated: OR = 0.11; booster vaccinated: OR = 0.28), diabetic nephropathy (partially vaccinated: OR = 0.23; fully vaccinated: OR = 0.50; booster vaccinated: OR = 0.30), and perceptions on the safety of COVID-19 vaccine (partially vaccinated: OR = 0.44; fully vaccinated: OR = 0.48; booster vaccinated: OR = 0.45) were all associated with the three of vaccination status.

Conclusion: This study showed that higher proportion of COVID-19 vaccine coverage among patients with DM in China. The concern about the safety of the COVID-19 vaccine affected the vaccine behavior in patients with DM. The COVID-19 vaccine was relatively safe for DM patients due to all side effects were self-limiting.

Keywords: COVID-19; China; diabetes mellitus; vaccine; vaccine uptake.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The COVID-19 vaccination status among patients with DM (n = 2200).
Figure 2
Figure 2
The reasons for not receiving COVID-19 vaccines (n = 271).
Figure 3
Figure 3
(A) The willingness for receiving the fourth dose of the COVID-19 vaccine among those who have finished the booster vaccination (n = 1434). (B) The reasons for being unwilling to receive the fourth dose of the COVID-19 vaccine (n = 460).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. . Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. New Engl J Med (2021) 384(23):2187–201. doi: 10.1056/NEJMoa2101544 - DOI - PMC - PubMed
    1. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. . Effectiveness of the pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ (Clinical Res ed) (2021) 373:n1088. doi: 10.1136/bmj.n1088 - DOI - PMC - PubMed
    1. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. . Association between mRNA vaccination and COVID-19 hospitalization and disease severity. Jama (2021) 326(20):2043–54. doi: 10.1001/jama.2021.19499 - DOI - PMC - PubMed
    1. Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. Jama (2021) 325(18):1896–8. doi: 10.1001/jama.2021.4388 - DOI - PMC - PubMed
    1. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol infect (2022) 28(2):202–21. doi: 10.1016/j.cmi.2021.10.005 - DOI - PMC - PubMed

Publication types

Substances